Welcome to the PRIMCAT Decision Support Tool
PRIMCAT is a Commonwealth funded multi-institutional research program that will support the decision-making processes of Australia’s Health Technology Assessment (HTA) agencies. PRIMCAT provides evidence-based, internationally validated forward estimates of the number of Australian individuals diagnosed with cancer who may benefit from new cancer treatments and the associated population health economic impacts for the health system.
More information about the objectives of PRIMCAT can be found on the research program webpage.
What is the PRIMCAT Tool?
The PRIMCAT Tool is underpinned by current Australian cancer treatment algorithms, the actual use of cancer treatments in real-world data and the prevalence of relevant gene mutations in the Australian cancer population. The Tool utilises discrete event simulation modelling to provide 5-year forecasts of the number of Australian individuals diagnosed with cancer who are eligible for treatment by disease stage and line of treatment.
This online simulation model predicts the impact of listing a new cancer treatment on the PBS and MBS, by forecasting the number of patients eligible for currently subsidised treatments, as well as scenario analyses for new treatments identified in horizon scanning.
Terms Of Use
By accessing or using the results associated with the PRIMCAT Decision Support Tool (PRIMCAT Tool), you are agreeing to be bound by our Terms Of Use, which are found on the Decision Support Tool within the tab "Terms Of Use", and you are acknowledging that you have read and understood the listed disclaimers.
The PRIMCAT Tool is a web-based tool that provides estimates of the number of individuals diagnosed with cancer who are eligible for current and future cancer treatments in Australia. It is an experimental technology derived from Australian data that has not yet been formally tested or approved for clinical use. Users of the PRIMCAT Tool should consult with qualified and appropriately experienced medical professionals when considering the information from the PRIMCAT Tool for diagnostic or treatment decisions. While considerable care has been taken, The University of Melbourne cannot, and does not make any representations and gives no warranties that the information associated with the PRIMCAT Tool is in every respect correct, current, complete, reliable, or suitable for any purpose and use is entirely at your own risk.
Citing the results and the PRIMCAT Decision Support Tool
The PRIMCAT Project (2023). PRedicting the population health economic IMpact of new and current CAncer Treatments [PRIMCAT Tool]. https://cancerhealthservices.shinyapps.io/primcat-tool, accessed .
Acknowledgments
PRIMCAT was funded by the Medical Research Future Fund (MRF1199701), MRFF Preventative and Public Health THSCOR 2019: Targeted Health Systems and Community Organisation Research.
All published materials are the responsibility of the research team and do not reflect the views of the Commonwealth.
We would like to thank all members of PRIMCAT:
Chief Investigators: Dr Fanny Franchini, Prof Maarten IJzerman, Prof Yuting Zhang, Prof Sallie-Anne Pearson, Prof Peter Gibbs, Prof Benjamin Solomon, Prof Grant McArthur, A/Prof Jayesh Desai, Prof Stephen Fox, Dr Koen Degeling.
Associate Investigators: Ms Sophy Athan, Prof Adam Elshaug, Prof Professor David Roder, Professor Sean Grimmond, Dr Marliese Alexander.
Consumer Panel: Ms Sophy Athan (Chair), Mr David Attwood, Mr Paul Baden, Mrs Wendy Benson, Ms Catherine Bressanutti, Mr George Jiang, Mrs Carolyn Rowan.
Study Team: Dr Fanny Franchini, Dr Koen Degeling, Dr Benjamin Daniels, Ms Karen Trapani, Dr Jennifer Soon, Dr Yat Hang To, Dr Ou Yang, Ms Sophie O'Haire, Mr Piers Gillett, Dr Judith Liu.